Vinva Investment Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Vinva Investment Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.64M	Sell	19,569 -2,272	-10%	-$124K	0.01%	309
2026 Q1	$1.75M	Buy	21,841 +14,619	+202%	+$852K	0.02%	296
2025 Q4	$636K	Sell	7,222 -91,181	-93%	-$4.96M	0.01%	331
2025 Q3	$5.32M	Buy	98,403 +67,309	+216%	+$3.85M	0.1%	178
2025 Q2	$1.72M	Buy	31,094 +20,620	+197%	+$1.21M	0.04%	255
2025 Q1	$748K	Buy	+10,474	New	+$705K	0.03%	300
2023 Q2	–	Sell	-2,588	Closed	-$247K	–	376
2023 Q1	$247K	Buy	+2,588	New	+$268K	0.02%	383

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vinva Investment Management's BMRN Position: Q2 2026 in Review

Vinva Investment Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 10% in Q2 2026, selling an estimated $124K and leaving 19,569 shares worth $1.64M. The position accounts for 0.01% of the portfolio, ranked #309.

Vinva Investment Management first reported a position in BMRN in Q1 2023 and has held it in 7 quarters since. The position peaked at $5.32M in Q3 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Vinva Investment Management held 19,569 shares of BioMarin Pharmaceuticals worth $1.64M as of Q2 2026.
Vinva Investment Management sold 2,272 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $124K.
BioMarin Pharmaceuticals made up 0.01% of Vinva Investment Management's portfolio in Q2 2026, its #309 holding.
Vinva Investment Management first reported a position in BioMarin Pharmaceuticals in Q1 2023 and has held it in 7 quarters since.
Vinva Investment Management's BioMarin Pharmaceuticals position peaked at $5.32M in Q3 2025.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Vinva Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.